How do you approach the re-challenge with trastuzumab in metastatic HER2+ patients who develop cardiomyopathy on trastuzumab/pertuzumab with subsequent improvement with discontinuation?

First, I send all my patients in this situation to the cardiologist. Second, I will re-start the treatment with close cardiology follow-up. Whether to re-load or not is an open question. I personally do not re-load, but I don’t think is wrong to re-load.